Volume 194, number 12: Treatment Benefit on Cerebrospinal Fluid HIV-1 Levels in the Setting of Systemic Virological Suppression and Failure
14th Nov 2006, 01:00 GMT
Objective. To characterize the effect of partially suppressive combination antiretroviral therapy on cerebrospinal fluid (CSF) human immunodeficiency virus (HIV)–1 RNA levels and CSF inflammation. Design. The study was a cross-sectional analysis of 139 HIV-1–infected subjects without active neurological disease, categorized as having successful therapy (plasma HIV-1 RNA level 500 copies/mL), having failure of therapy (plasma HIV-1 RNA level >500 copies/mL), or not receiving therapy. The control group consisted of 48 HIV-negative subjects. CSF and plasma HIV-1 RNA assays had a lower limit of quantification of 2.5 copies/mL. Genotypic resistance testing was performed on a subset of subjects. Results. Of the 47 subjects with successful therapy, CSF HIV-1 RNA levels were 500 copies/mL. Although plasma HIV-1 RNA levels were similar in 35 subjects with failed therapy and 57 of those not receiving therapy ([FORMULA]), CSF HIV-1 RNA levels were at least 10-fold lower in subjects with failed therapy ([FORMULA]). This disproportionate effect of treatment on CSF HIV-1 RNA levels was found across the range of plasma HIV-1 RNA levels and was not explained by differences in levels of drug resistance in plasma or CSF. Therapy reduced CSF inflammation in both treated groups. Conclusions. In our cohort, antiretroviral therapy had a greater effect on HIV-1 RNA levels in CSF than in plasma and reduced intrathecal inflammation, even in the presence of drug resistance.
Volume 194, number 12: Treatment Benefit on Cerebrospinal Fluid HIV-1 Levels in the Setting of Systemic Virological Suppression and Failure related news:
- Interim Analysis of New Study Suggests Boosted INVIRASE May Achieve Similar Levels of HIV Suppression to Boosted Lopinavir with a Favorable Lipid Profile — Pharmaceuticals News from StratCenter.com
- Interim Analysis Of New Study Suggests Boosted INVIRASE(R) May Achieve Similar Levels Of HIV Suppression To Boosted Lopinavir — Health News from Medical News Today
- Volume 194, number 12: Cyclosporin A Provides No Sustained Immunologic Benefit to Persons with Chronic HIV-1 Infection Starting Suppressive Antiretroviral Therapy: Results of a Randomized, Controlled Trial of the AIDS Clinical Trials Group A5138 — J Infect Dis Latest Issue
- Volume 194, number 12: Immune-Based Therapy for HIV Infection: Are Acute and Chronic HIV Infection Different Diseases? — J Infect Dis Latest Issue
- An HIV-positive patient receives treatment at the Nouakchott ... — Health Photos on Yahoo! News Photos
- Volume 194, number 12: Phase 1 Safety and Immunogenicity Evaluation of a Multiclade HIV-1 Candidate Vaccine Delivered by a Replication-Defective Recombinant Adenovirus Vector — J Infect Dis Latest Issue
- Health Secretary Mike Leavitt smiles in front of an anti-HIV/AIDS ... — Top Stories Photos - Reuters on Yahoo! News Photos
- Volume 194, number 12: Clinical and Immunologic Risk Factors for Meningococcal C Conjugate Vaccine Failure in the United Kingdom — J Infect Dis Latest Issue
- Volume 194, number 12: Recurrence of Symptomatic Bacterial Vaginosis 12 Months after Oral Metronidazole Therapy in HIV-Positive and -Negative Women — J Infect Dis Latest Issue
- Volume 194, number 12: Phase 1 Clinical Trials of the National Institutes of Health Vaccine Research Center HIV/AIDS Candidate Vaccines — J Infect Dis Latest Issue
Latest news from J Infect Dis Latest Issue:
- Volume 194, number 12: Phase 1 Safety and Immunogenicity Evaluation of a Multiclade HIV-1 Candidate Vaccine Delivered by a Replication-Defective Recombinant Adenovirus Vector
- Volume 194, number 12: Phase 1 Safety and Immunogenicity Evaluation of a Multiclade HIV-1 DNA Candidate Vaccine
- Volume 194, number 12: Quantification of Viral Inactivation by Photochemical Treatment with Amotosalen and UV A Light, Using a Novel Polymerase Chain Reaction Inhibition Method with Preamplification
- Volume 194, number 12: Cyclosporin A Provides No Sustained Immunologic Benefit to Persons with Chronic HIV-1 Infection Starting Suppressive Antiretroviral Therapy: Results of a Randomized, Controlled Trial of the AIDS Clinical Trials Group A5138
- Volume 194, number 12: Evaluation of Purified Taenia solium Glycoproteins and Recombinant Antigens in the Serologic Detection of Human and Swine Cysticercosis
- Volume 194, number 12: Phase 1 Clinical Trials of the National Institutes of Health Vaccine Research Center HIV/AIDS Candidate Vaccines
- Volume 194, number 12: Is There a Safe Age for Vaccinating Infants with Tetravalent Rhesus-Human Reassortant Rotavirus Vaccine?
- Volume 194, number 12: Reply to Gargiullo et al.
- Volume 194, number 12: Is Panton-Valentine Leukocidin the Major Virulence Determinant in Community-Associated Methicillin-Resistant Staphylococcus aureus Disease?
- Volume 194, number 12: Human Cytolytic T Cell Recognition of Yersinia pestis Virulence Proteins That Target Innate Immune Responses